New real-world data from the 1INSPIRE study shows that frontline niraparib (Zejula) maintenance is well-tolerated in patients ...

Mirvetuximab soravtansine shows 16.4-month OS in ovarian cancer, though poor ECOG status and toxicity significantly impact ...

Because the immune system resides beneath the skin's barrier, the initial cellular mutation caused by UV light occurs before ...

Dr. Don Dizon discusses why early fertility referral and avoiding clinical assumptions are vital for young breast cancer patients at diagnosis. According to Dizon, the discussion regarding fertility ...

Alembic Pharmaceuticals Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its ...

Explore how Jessica MacIntyre, ONS President, is transforming oncology care through APP fellowships, a new skin toxicity ...

Letrozole monotherapy failed to show noninferiority compared to standard chemotherapy followed by letrozole as a first-line ...

Anu Agarwal, vice president of global cancer support at the American Cancer Society, outlined key barriers facing oncology ...

Gotistobart reduced the risk of death by 54% and doubled 12-month survival compared with chemotherapy in previously treated ...

Shachar emphasized that the key takeaway is the need for proactive and consistent toxicity monitoring across all patients ...

The SISTER trial finds 1:1 peer support significantly improves endometrial cancer treatment completion for Black women, per ...